{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:26Z","timestamp":1792078946673,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009043","name":"University of Patras","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009043","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40256-022-00559-0","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T01:02:22Z","timestamp":1671498142000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"given":"Grigorios","family":"Tsigkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Apostolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Trigka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Chlorogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil S.","family":"Brilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Davlouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"559_CR1","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72:2915\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"559_CR3","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STA guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134:e123\u201355.","journal-title":"Circulation"},{"key":"559_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"J-P Collet","year":"2021","unstructured":"Collet J-P, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289\u2013367.","journal-title":"Eur Heart J"},{"key":"559_CR5","first-page":"e21","volume":"2022","author":"JS Lawton","year":"2021","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;2022:e21-129.","journal-title":"J Am Coll Cardiol"},{"key":"559_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.carrev.2021.06.004","volume":"33","author":"E Shlofmitz","year":"2021","unstructured":"Shlofmitz E, Case BC, Chen Y, Chezar-Azerrad C, Hashim H, Garcia-Garcia HM, et al. Waksman in-stent restenosis classification: a mechanism-based approach to the treatment of restenosis. Cardiovasc Revasc Med. 2021;33:62\u20137.","journal-title":"Cardiovasc Revasc Med"},{"key":"559_CR7","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.jcmg.2017.09.008","volume":"10","author":"A Maehara","year":"2017","unstructured":"Maehara A, Matsumura M, Ali ZA, Mintz GS, Stone GW. IVUS-guided versus OCT-guided coronary stent implantation: a critical appraisal. JACC Cardiovasc Imaging. 2017;10:1487\u2013503.","journal-title":"JACC Cardiovasc Imaging"},{"key":"559_CR8","doi-asserted-by":"crossref","unstructured":"Hahn J-Y, Song Y Bin, Oh J-H, Cho D-K, Lee JB, Doh J-H, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391:1274\u201384.","DOI":"10.1016\/S0140-6736(18)30493-8"},{"key":"559_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"559_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"559_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058327","volume":"8","author":"V Fidler","year":"2013","unstructured":"Fidler V, Nagelkerke N. The Mantel-Haenszel procedure revisited: models and generalizations. PLoS ONE. 2013;8: e58327.","journal-title":"PLoS ONE"},{"key":"559_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"559_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375.","journal-title":"J Clin Epidemiol"},{"key":"559_CR14","doi-asserted-by":"publisher","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la. Lancet. 2018;392:940\u20139. https:\/\/doi.org\/10.1002\/central\/CN-01649861\/full.","DOI":"10.1002\/central\/CN-01649861\/full"},{"key":"559_CR15","doi-asserted-by":"publisher","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321:2428\u201337. https:\/\/doi.org\/10.1002\/central\/CN-01951597\/full.","DOI":"10.1002\/central\/CN-01951597\/full"},{"key":"559_CR16","doi-asserted-by":"publisher","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414\u201327. https:\/\/doi.org\/10.1002\/central\/CN-01951598\/full.","DOI":"10.1002\/central\/CN-01951598\/full"},{"key":"559_CR17","doi-asserted-by":"publisher","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381:2032\u201342. https:\/\/doi.org\/10.1002\/central\/CN-01997924\/full.","DOI":"10.1002\/central\/CN-01997924\/full"},{"key":"559_CR18","doi-asserted-by":"publisher","unstructured":"De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019;15:e990\u20138. https:\/\/doi.org\/10.1002\/central\/CN-02012273\/full.","DOI":"10.1002\/central\/CN-02012273\/full"},{"key":"559_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"B-K Kim","year":"2020","unstructured":"Kim B-K, Hong S-J, Cho Y-H, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323:2407\u201316.","journal-title":"JAMA"},{"key":"559_CR20","doi-asserted-by":"publisher","unstructured":"Hong SJ, Kim JS, Hong SJ, Lim DS, Lee SY, Yun KH, et al. 1-Month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial. JACC Cardiovasc Interv. 2021;14:1801\u201311. https:\/\/doi.org\/10.1002\/central\/CN-02301849\/full.","DOI":"10.1002\/central\/CN-02301849\/full"},{"key":"559_CR21","doi-asserted-by":"publisher","unstructured":"Valgimigli M, Frigoli E, Heg D, Tijssen J, J\u00fcni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385:1643\u201355. https:\/\/doi.org\/10.1002\/central\/CN-02340226\/full.","DOI":"10.1002\/central\/CN-02340226\/full"},{"key":"559_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcin.2021.09.037","volume":"15","author":"G Tsigkas","year":"2022","unstructured":"Tsigkas G, Papageorgiou A, Moulias A, Kalogeropoulos AP, Papageorgopoulou C, Apostolos A, et al. Distal or traditional transradial access site for coronary procedures: a single-center, randomized study. JACC Cardiovasc Interv. 2022;15:22\u201332.","journal-title":"JACC Cardiovasc Interv."},{"key":"559_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.recesp.2020.03.013","volume":"74","author":"M Verdoia","year":"2021","unstructured":"Verdoia M, Khedi E, Suryapranata H, De Luca G. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Rev Esp Cardiol. 2021;74:140\u20138.","journal-title":"Rev Esp Cardiol"},{"key":"559_CR24","doi-asserted-by":"crossref","unstructured":"Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Hear journal Cardiovasc Pharmacother. 2021;7:86\u201393.","DOI":"10.1093\/ehjcvp\/pvaa001"},{"key":"559_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ahj.2022.05.019","volume":"251","author":"DY Park","year":"2022","unstructured":"Park DY, Wang P, An S, Grimshaw AA, Frampton J, Ohman EM, et al. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2022;251:101\u201314.","journal-title":"Am Heart J"},{"key":"559_CR26","doi-asserted-by":"crossref","unstructured":"Giacoppo D, Matsuda Y, Fovino LN, D\u2019Amico G, Gargiulo G, Byrne RA, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clini. Eur Heart J. 2021;42:308\u201319.","DOI":"10.1093\/eurheartj\/ehaa739"},{"key":"559_CR27","doi-asserted-by":"publisher","unstructured":"Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, et al. Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis. JACC Cardiovasc Interv. 2021;14:444\u201356. https:\/\/doi.org\/10.1002\/central\/CN-02336026\/full.","DOI":"10.1002\/central\/CN-02336026\/full"},{"issue":"7","key":"559_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ehjcvp\/pvac020","volume":"8","author":"W Ullah","year":"2022","unstructured":"Ullah W, Zahid S, Sandhyavenu H, Faisaluddin M, Khalil F, Pasha AK, et al. Extended, standard or De-escalation antiplatelet therapy for patients with CAD undergoing PCI? A trial-sequential, bivariate, influential and network meta-analysis. Eur Hear J Cardiovasc Pharmacother. 2022;8(7):717\u201327.","journal-title":"Eur Hear J Cardiovasc Pharmacother."},{"key":"559_CR29","doi-asserted-by":"publisher","unstructured":"Koo B-K, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487\u201396. https:\/\/doi.org\/10.1002\/central\/CN-02293020\/full.","DOI":"10.1002\/central\/CN-02293020\/full"},{"issue":"3","key":"559_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"issue":"Supplement_2","key":"559_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2717","volume":"43","author":"A Apostolos","year":"2022","unstructured":"Apostolos A, Trigka A, Chlorogiannis D, Vasilagkos G, Chamakioti M, Spyropoulou P, Karamasis G, Dimitriadis K, Moulias A, Katsanos K, Tsioufis C, Toutouzas K, Alexopoulos D, Davlouros P, Tsigkas G. 2022 Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis. European Heart Journal 43(Supplement_2). https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.2717","journal-title":"European Heart Journal"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00559-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00559-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00559-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:05:10Z","timestamp":1674273910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00559-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00559-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"1 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this articles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Grigorios Tsigkas has received advisory board\/lecturing fees from Astra Zeneca, Menarini, Pfizer, and Boehringer Ingelheim. Konstantinos Toutouzas has received honorarium from Sanofi Adventist. Dimitrios Alexopoulos has received advisory board\/lecturing fees from Astra Zeneca, Bayer, Pfizer, Boehringer Ingelheim, Medtronic, Biotronik, and Chiesi Hellas. Emmanouil S. Brilakis has received consulting\/speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Elsevier, GE Healthcare, IMDS, InfraRedx, Medicure, Medtronic, Opsens, Siemens, and Teleflex; and research support from Boston Scientific, GE Healthcare. He is also an owner of Hippocrates LLC; and a shareholder of MHI Ventures, Cleerly Health, and Stallion Medical. Periklis Davlouros has received advisory board\/lecturing fees from Astra Zeneca, Bayer, Menarini, Pfizer, and Boehringer Ingelheim. Anastasios Apostolos, Aikaterini Trigka, Dimitrios Chlorogiannis, and Konstantinos Katsanos declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GT, AA, and PD designed the analysis. AA, AT, and DC collected the data. AA and KK performed the analysis. GT and AA wrote the manuscript. KT, DA, ESB, and PD reviewed the manuscript. All authors approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}